SUMMARY Background
Whether therapeutic drug monitoring for adalimumab needs to be performed at trough has not been defined.
Aim
To determine intra-patient adalimumab drug-level variation and to identify modulating patient and disease factors.
Methods
In this prospective observational study, adult patients with Crohn's disease established on maintenance adalimumab had drug levels measured repeatedly according to pre-defined schedules (visit 1: day 4-6, visit 2: day 7-9, trough: day 13-14) across two consecutive fortnightly cycles. Disease activity was assessed using Harvey-Bradshaw Index, C-reactive protein and faecal calprotectin. For this analysis, trough levels ≥4.9 lg/mL were considered therapeutic.
Results
Nineteen patients underwent 111 evaluations. Mean intra-patient drug levels from paired visits between cycles did not differ (visit1 cycle1: 4.81, cycle2: 5.21 lg/mL, P = 0.24, visit2 cycle1: 4.86, cycle2: 4.82, P = 0.91 and trough cycle1: 3.95, cycle2: 3.95, P = 0.99), irrespective of disease activity. Drug levels were stable over the first 9 days (visit 1-2), but declined to trough by a mean 1.06 and 0.89 lg/mL between visit 1 or 2, respectively (P < 0.001). Models using nontemporal factors (smoking, syringe delivery device) and levels at earlier visits accounted for 66-80% of the variance in trough levels. On receiver-operating curve analysis, thresholds identified in the first 9 days that predicted a therapeutic trough level were similar to the trough threshold itself, with high sensitivity but modest specificity.
Conclusion
While therapeutic drug monitoring should be performed at trough, a drug level ≥4.9 lg/mL obtained during the first 9 days predicts a therapeutic trough drug level with reasonable confidence. 
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INTRODUCTION
Infliximab and adalimumab are effective agents for the induction and maintenance of remission in luminal and fistulising Crohn's disease [1] [2] [3] [4] and ulcerative colitis. 5, 6 Despite their effectiveness, 5-10% fail to respond to induction and a further 15-54% of patients subsequently lose response by 12 months, depending on the definition employed. 7 Increased clearance of the drug leading to low serum concentrations often underpins primary nonresponse and secondary loss of response, due to the development of anti-drug antibodies [8] [9] [10] and other nonimmune mechanisms that increase drug clearance. 10, 11 A shift of disease away from a predominant TNF-a pathway to involve other mediators has also been implicated. 7, 10 Managing and preventing loss of response is a key issue in inflammatory bowel disease because few alternative agents exist, unlike in other chronic autoimmune diseases, where a raft of monoclonal antibodies are available.
In this regard, there is a growing body of evidence supporting the use of therapeutic drug monitoring of infliximab and adalimumab. Undetectable or low infliximab trough levels (taken immediately before the scheduled dose) are associated with worse clinical outcomes [12] [13] [14] [15] and the therapeutic range associated with clinical remission using ELISA based assays is between 3 and 7 lg/mL. [16] [17] [18] [19] Although some studies have demonstrated a similar relationship with adalimumab, 1, 20 others have found no association between drug levels and clinical outcomes. 21 There is also a relative paucity
of data identifying what is a 'therapeutic cut-off'. 22 Differences between assays used, the sample timing and the pharmacokinetics of infliximab and adalimumab may explain these discrepant results. Moreover, it is likely that more data exist for infliximab simply because it is easier to sample drug levels at trough when the patient presents for their scheduled infusion, rather than recruit patients treated with adalimumab who self-administer the drug at home. The subcutaneous delivery of adalimumab leads to very different concentration-time profiles to intravenously delivered infliximab, which yields high peak concentrations and low trough levels, whereas adalimumab exhibits more uniform concentration-time profiles at steady state. Thus, it is possible that drug-level sampling can be performed at any time-point during a fortnightly cycle, rather than at trough as utilised for infliximab, but the validity of this approach has yet to be demonstrated in a well-designed study. 23 Hence, the present study has aimed to address the hypothesis that there are minimal variations of adalimumab drug levels between and within a cycle, by assessing and comparing intra-individual adalimumab drug levels at multiple time-points during and between fortnightly dosing regimens amongst patients with Crohn's disease, and to examine potential modulating factors thereof. In other words, we wished to determine how confident a clinician can be that a single 'spot' drug level truly reflects pharmacokinetics, assuming that these are closely related to pharmacodynamics.
METHODS
Patients
Eligible patients, 18 years of age or greater, with Crohn's disease were recruited between July 2014 and August 2015 from the inflammatory bowel disease out-patient clinics of the Alfred Hospital and Eastern Health, Melbourne, Australia. The diagnosis of Crohn's disease was based on standard endoscopic, histopathological and radiological criteria. 24 All patients were established on maintenance adalimumab 40 mg every other week (defined as >14 weeks of treatment) and their disease activity appeared clinically stable. Where prescribed, concomitant immunomodulators (azathioprine, mercaptopurine or methotrexate) were maintained at a stable dose for at least 12 weeks prior to enrolment and continued throughout the study at the same dose. No patients received concurrent corticosteroids. All patients provided written informed consent. The study was approved by the institutional ethics review committees of the participating centres.
Study design
Patients attended at each time-point of days 4-6 ('visit 1'), days 7-9 ('visit 2') and days 13-14 ('trough') across two consecutive 14-day adalimumab treatment cycles (cycle 1 and 2), where day 1 was the first day after the last adalimumab dose. At each study visit, clinical disease activity was assessed using the Harvey-Bradshaw Index (HBI) 25 
Laboratory methods
Adalimumab serum levels were measured using a commercial sandwich enzyme-linked immunosorbent assay (ELISA) (Shikari Q-ADA; Matriks Biotek, Ankara, Turkey) as per manufacturer's instructions. All samples were measured in duplicate and the average reported in lg/ mL. The samples were diluted with the kit assay buffer at either 1:20, 1:10 or 1:4 as required and the concentration determined from the standard curve multiplied by the dilution factor. The upper limit of the assay was 20 lg/mL and the lower limit of quantification was 0.1 lg/mL. A trough adalimumab level <4.9 lg/mL was defined as sub-therapeutic. 20 Given the assay used in our institution is drug sensitive, assessment for anti-drug antibodies were only performed on samples with a drug level <1.5 lg/mL and reported as detectable or undetectable. CRP serum levels were measured using an in vitro diagnostic assay on Architect ci16200 analyser (Abbott Laboratories, Abbott Park, IL, USA). Faecal calprotectin was measured in duplicate on extracts of 50 mg of homogenised stool by ELISA (B€ uhlmann Laboratories, Basel Switzerland) as per manufacturer's instructions. The results were reported as lg/g faeces.
Statistical analyses
Categorical variables are presented as number and percentage, and quantitative data as mean with standard deviation or median with interquartile range (IQR). Comparisons between patient groups were carried out using Pearson chi-square test, independent sample t-test or Mann-Whitney U-test, as appropriate. Linear mixed models for drug levels were fitted to investigate inter and intra-patient variation and to test for significant differences between cycles, visits and their two-way interaction. Univariate and multivariate linear regression models for trough drug level and logistic regression models for the achievement of a therapeutic drug level at trough were evaluated for the following factors and covariates: gender, cycle (1st or 2nd), smoking status, delivery device (DDD), weight at study entry, body mass index (BMI), use of concomitant immunomodulation, drug level at visits 1 and 2, serum albumin and indices of disease activity (HBI, CRP and faecal calprotectin). A stepwise regression procedure, based on t-tests for adding or dropping terms from the linear regression models, was used to find a parsimonious best model. A similar stepwise procedure, based on Wald Test p-values, was used in the exploration of the logistic regression models. Models were fitted using the GenStat statistical package version 17 (VSN International Ltd, Hemel Hempstead, UK) and receiver-operator characteristic (ROC) curves for logistic regression models were produced using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
Nineteen patients (11 female, 58%) underwent 111 evaluations; one patient did not attend for blood testing during the second cycle. Mean age was 39.2 (s.d. 9.5) years and median disease duration was 11 (IQR, 6-18) years. 7/19 (37%) were smokers and 14/19 (74%) were co-treated with an immunomodulator. Pen delivery device was used in 16/19 (84%) and all patients administered adalimumab into the abdomen. Patient demographics are shown in Table 1 . Clinically active disease was observed in 30% of visits (28% and 35% of patients in cycle 1 and 2, respectively), systemic inflammation in 36% of visits (37% and 33% of patients in cycle 1 and 2, respectively) and elevated faecal calprotectin in 35% of visits (26 and 39% of patients in cycle 1 and 2 respectively).
Adalimumab drug levels
Drug levels at all time-points in individual patients are shown ( Figure 1 ). Summary data are shown in Table 2 . Variation in drug levels was predominantly between patients. At trough, 23/37 (62%) were sub-therapeutic.
Between-cycle differences. Drug levels did not differ significantly between cycles (P = 0.542) and the differences between visits did not differ between cycles (P = 0.604). In only one of the 18 patients did the qualitative assessment of therapeutic vs. sub-therapeutic (<4.9 lg/mL) at trough change across cycles (cycle 1: 2.49, cycle 2: 5.12 lg/mL).
Between-visit differences. Drug levels were similar between visit 1 and 2, with means (S.E.M.) of 5.01 (0.37) and 4.84 lg/mL (0.40), respectively (P = 0.49). Levels declined significantly from both visits 1 and 2 to the trough level of 3.95 lg/mL (0.35) (P < 0.001 for both). This equated to a mean fall of 0.17 (3%) from visit 1 (day 4-6) to visit 2 (day 7-9), 0.89 (18%) from visit 2 (day 7-9) to trough (day [13] [14] , and 1.06 lg/mL (21%) from visit 1 (day 4-6) to trough (day 13-14) (Figure 2 ). The declines in drug levels over the visits in each cycle were similar (visit 1-2: Pearson's r = 0.869; 1-3: r = 0.765; and 2-3: r = 0.860).
Anti-drug antibodies 10/111 (9%) of samples, collected from three patients with a drug level <1.5 lg/mL, were analysed for the presence of detectable anti-drug antibodies; of these none were positive.
Relationship between drug levels and disease activity There was substantial overlap in median drug levels between patients with active disease compared to those in remission at visit 1, visit 2 or at trough, regardless of the definition employed ( Figure 3) . No difference in drug levels were observed for clinical remission compared with active disease (HBI < 5, P = 0.46, 0.66, 0.72 for visit 1, 2 and trough, respectively), absence compared with presence of systemic inflammation (CRP >3 mg/L, P = 0.81, 0.79 and 0.6 for visit 1, 2 and trough, respectively) and mucosal healing (P = 0.61).
Relationship between nontrough drug levels, covariates of interest and trough drug levels Predictive models that included drug levels at visit 1 or 2 and other potentially relevant covariates were constructed using univariate and multivariate linear regression. As shown in Table 3 , factors predictive of trough drug levels via univariate analysis included drug levels at visit 1 and 2 (P < 0.001), smoking (P = 0.04) and syringe delivery device used (P = 0.036).
In multiple regression analysis, increases in trough drug levels were independently predicted by increases in levels at visit 1 (b = 0.625, P < 0.001), and an increase with syringe delivery (b = 1.795, P = 0.005), but lower trough levels were predicted by smoking (b = À1.038, P = 0.034) (R 2 = 65.9%). In a similar model, increases in trough drug levels were predicted by increases in levels at visit 2 (b = 0.681, P < 0.001) and an increase with syringe delivery (b = 1.602, P = 0.001), but a decline in trough levels was predicted by smoking (b = À0.864, P = 0.022), (R 2 = 80.0). In these multivariate regression models, indices of active disease (CRP, faecal calprotectin and HBI) were not significantly associated with trough levels, although a trend was observed for lower levels with active mucosal inflammation as assessed by faecal calprotectin. No relationship was observed between patient weight or BMI and trough drug levels.
Predictors of therapeutic drug levels
Logistic regression analysis was performed to identify pharmacokinetic and pharmacodynamic factors associated with achieving a therapeutic adalimumab trough level (≥4.9 lg/mL). As shown in Table 4 , levels at visit 1 and 2 † One patient did not attend visits during second cycle. ‡ Faecal calprotectin missing from 1 patient. § Blood testing missing from 1 visit. A1 = age ≤16, A2 = 17-40 and A3 = ≥40 years. B1 = nonstricturing, nonpenetrating, B2 = stricturing, B3 = penetrating behaviour, L1 = ileal, L2 = colonic, L3 = ileocolonic disease location.
were significant predictors of a therapeutic trough level. The corresponding ROC curves and threshold concentrations for visit 1: AUC = 0.851, Youden Index = 4.93 lg/mL (sensitivity = 100%, specificity = 65.2%), Optimal Cut-off = 5.07 lg/mL (sensitivity = 92.9%, specificity = 69.6%) and for visit 2: AUC = 0.866, Youden Index = Optimal Cut-off = 4.72 lg/mL (sensitivity = 100%, specificity = 69.6%), are displayed in Figure 4a ,b, respectively. Logistic regression curves in which the probability of achieving of a therapeutic level at trough were also constructed ( Figure S1a,b) . These show, for example, that the values of drug levels that corresponded to an 80% predicted probability of achieving a therapeutic trough drug level were 7.94 (95% CI: 6.53-16.49) lg/mL at visit 1 and 7.35 (95% CI: 6.21-12.09) lg/mL at visit 2.
DISCUSSION
The treating clinician's confidence in whether a single adalimumab drug level test is clinically applicable -both in terms of between and within cycles of treatment -is critical to apply therapeutic drug monitoring to patients with Crohn's disease being treated with adalimumab. The current prospective observational study assessed such issues within and between consecutive cycles in patients with relatively stable disease with several findings of clinical significance. First, the drug level at any point in a cycle reliably predicts the levels in the subsequent cycle. Second, drug levels were relatively stable between visit 1 and 2 (the first 9 days of a 2-week cycle), but a consistent decline in levels were noted beyond this Figure 2 | Absolute difference (delta) in adalimumab drug levels between visits. Long horizontal bars represent mean delta. Statistical differences in delta from zero were observed between V1 to T (P < 0.0001) and V2 to T (P < 0.0001, one sample t-test). No difference was seen between V1 to V2 (P = 0.43). V1 = visit 1 (day 4-6), V2 = visit 2 (day 7-9), T = trough (day 13 or 14) point towards the nadir of the trough level, which has been used as the 'gold standard' for decision-making via therapeutic drug monitoring. Third, a threshold similar to that taken at trough when tested within the first 9 days of a cycle predicted a therapeutic trough level, with a very high sensitivity but specificity of 65-70%. Finally, nontemporal factors -syringe rather than pen as delivery device (albeit with very small numbers) and current smoking -were independently associated with trough drug levels. These enabled predictive models to be created, which, incorporating drug levels at either visit 1 or 2, accounted for 66% and 80% of the variation in trough levels respectively.
While serum levels of infliximab have been associated with clinical outcomes in multiple studies, fewer data exist for adalimumab and are not consistent in their conclusions. Very low levels clearly discriminate poor from better outcomes and measurement of drug levels in the setting of patients losing response to adalimumab in this way has clinical utility. The more controversial area has been in the definition of threshold cut-off values that could discriminate between patients by remission status. Nevertheless, the practicality of measuring trough levels is more challenging for a self-administered drug, as opposed to infliximab where obtaining serum just prior to the next infusion is simple and reliable. Some have proposed that adalimumab therapeutic drug monitoring can be performed at any time-point in a treatment cycle, due to the relatively flat peak-trough pharmacokinetics observed with subcutaneously administered monoclonal antibodies. 23, 27, 28 Few data are available describing the pharmacokinetics of adalimumab in patients with Crohn's disease. In a post-hoc analysis of 341 adalimumab samples collected from 65 patients with Crohn's disease, large inter-individual differences in volume of distribution and clearance were observed, and elimination half-life in the absence of antibodies to adalimumab was 22 days. 29 In patients with rheumatoid arthritis, the time-to-peak plasma concentration was 9.1 days, clearance being increased in men and those with higher weight. 30 However, there is no published information on the variability within and across subsequent 14-day treatment cycles of adalimumab drug levels in patients with Crohn's disease. In the current cohort, no significant differences in intra-patient drug levels were observed between consecutive cycles, suggesting the results of a single drug level may be interpreted with confidence and do not need to be repeated immediately from one cycle to the next. This does not imply that drug levels will remain similar . Horizontal bars represent median drug levels. V1 = visit 1 (day 4-6), V2 = visit 2 (day 7-9), T = trough (day [13] [14] throughout a patient's disease course, as multiple factors that include variation in disease activity, emergence of anti-drug antibodies and changes in concomitant immunomodulation can all affect clearance of the drug and hence the levels obtained. 10 The patients in the present study were selected on the basis of general stability of disease activity and of concomitant medication. Although some changes in inflammatory indices were observed, few of these indicated clinically significant disease flares. Measured drug levels within treatment cycles were relatively stable over the first 9 days (visit 1 to visit 2) but did decline from day 4-6 to trough (À1.06 lg/mL) and day 7-9 to trough (À0.89 lg/mL, each P < 0.001). Such falls were similar in patients with currently active disease compared to those in remission on the basis of faecal calprotectin and CRP levels or clinical disease activity criteria. The big issue then is whether changes, all of small magnitude, can be accounted for in clinical decision-making. Two approaches were taken in an attempt to answer this question -correcting the results to accurately compute the trough level and using simple different cut-off values to provide accurate information for clinical decision-making.
In the first approach, linear regression modelling was performed and two nontemporal covariates, smoking and the drug delivery device used, were identified. Combining these with the drug level at visit 1 or 2 accounted for 66 and 80% of the variance in trough drug levels, respectively. To our knowledge, this is the first study demonstrating that smoking might influence adalimumab pharmacokinetics; further, this relationship was independent of disease activity. Although the deleterious effect interaction between smoking and Crohn's disease is recognised, 31 studies have yet to demonstrate a difference in anti-TNF drug levels according to smoking status. 23, [32] [33] [34] [35] A finding of potential interest was the apparent influence of the delivery device used in predicting adalimumab trough levels. A single study, presented in abstract form only, found no discrepancy in the bioavailability of adalimumab between the delivery device (pen or syringe) or the injection site (abdomen or thigh) after a single dose amongst healthy volunteers. 36 Intuitively, patient factors such as administration technique or inconsistent bioavailability due to variable absorption might explain these findings, but this warrants further evaluation. Given the small number of patients that administered adalimumab by syringe (n = 3), this finding should be interpreted with caution; it is hypothesis-generating and warrants further evaluation in a larger cohort. Other patient characteristics such as BMI, weight and concomitant immunomodulation, and disease factors such as active inflammation and serum albumin have been shown elsewhere to influence anti-TNF pharmacokinetics. 23, 37 Interestingly, we found no such relationship in this cohort, which may be explained by our limited sample size. In the second approach, the ability of an early cycle drug level at a specific cut-off value to accurately predict a therapeutic trough concentration was explored. A level of 4.9 lg/mL was chosen for the current analysis as this has been applied in several studies. 20, 38 This was approached using two related statistical methods. The first was ROC analysis that identified with a respectable AUC (>0.85) threshold drug concentrations at visits 1 or 2 which were almost the same as the therapeutic trough cut-off itself (Figure 4a,b) . The second approach was to compute logistic regression curves in which the probability of achieving a therapeutic level at trough could be determined from drug levels obtained at earlier points in a fortnightly treatment cycle. If an 80% probability was desired, then a drug level of 7.94 after 4-6 days and 7.35 lg/mL after 7-9 days would need to be seen. The clinical application of this information that might initially appear somewhat paradoxical depends upon the precision and predictability required by the physician. Thus, using the ROC analysis, a drug level any day within the first 9 days of the adalimumab treatment cycle can be considered qualitatively equivalent of the likely trough level in that cycle if a false-positive rate of 30-35% is considered acceptable clinically (as it is for many tests used). The precision of prediction together with its 95% confidence intervals can be evaluated using the logistic regression curves ( Figure S1a,b) . There are several limitations in this study. First, because of its small sample size, conclusions should be interpreted with caution and require validation in larger replication cohorts. It is likely that the precision of regression equations and cut-off values observed would be improved with much larger samples. Second, adalimumab administration was unsupervised, hence patients may have not administered adalimumab strictly every 14 days, which may have influenced the variability in intra-patient drug level. Nonadherence to medical therapies is well recognised in inflammatory bowel disease, 39 including patients treated with adalimumab. 40 However, this effect is likely to be small given no significant differences in intra-patient drug levels were observed between paired visits across subsequent cycles (P = 0.6). Third, in the linear and logistic regression analyses the clustering of cycles (almost always two cycles) within patients was not explicitly modelled -a future study in a larger cohort could explore correlations between and within cycles. However, we did note, in exploratory mixed model analyses of the drug levels, that complex withincycle correlation structures such as autoregressive and banded models, did not improve the goodness of fit of the model used to calculate the visit means in Table 2 . Fourth, the finding that syringe delivery device was an independent predictor of trough drug levels should be interpreted with caution given only three patients administered adalimumab by this method. Fifth, among smokers, we did not quantify the number of cigarettes per day or duration of smoking. Some studies in patients with Crohn's disease have found no impact of smoking on disease outcomes and that, rather, the degree of smoking may be more important. Hence, individual patient smoking patterns may influence the value identified as a covariate in the models we have proposed. Unlike drug tolerant assays such as the homogeneous mobility shift assay, our ELISA is unable to detect anti-drug antibodies in the presence of detectable drug due to interference. Immunogenicity is a well-recognised phenomena associated with increased anti-TNF drug clearance. 10 Accordingly, we did not observe detectable drug antibodies in this cohort of samples, and hence we could not explore the hypothesis that bound anti-drug antibodies early in a treatment cycle may be associated with increased drug clearance to trough. Finally, we used faecal calprotectin as a surrogate of mucosal healing, defining a cut-off of >150 lg/mL as being associated with active disease. A range of cut-off values have been proposed in the literature ranging from 50 to 400 lg/mL. 41 Acceptable correlation with validated endoscopic activity scores in Crohn's disease have been reported, 42 but whether this accuracy extends to isolated small bowel disease remains debated. Points labeled by DL1
Points labeled by DL2 Figure 4 | Relationship between drug levels at visit 1 (a) and visit 2 (b) and trough levels according to ROC analysis for achieving therapeutic trough level (≥4.9 lg/mL). DL1 = drug level at visit 1, DL2 = drug level at visit 2.
In conclusion, this study has demonstrated that adalimumab drug levels vary little during the first 9 days of a 14-day treatment cycle, but then decline thereafter to trough in patients with Crohn's disease. The results of a single drug level can be interpreted with confidence as intra-patient drug levels appear to remain consistent between subsequent cycles, acknowledging that factors known to influence the pharmacokinetics of adalimumab remain constant (including, but not limited to, disease activity, anti-drug antibodies and use of concomitant immunomodulation). Trough concentrations might be more accurately estimated from drug levels obtained during the first 9 days by considering the drug delivery device used and the negative effect of smoking status in each case. We recommend that therapeutic drug monitoring of adalimumab is performed at trough, however, if this is not possible, a level obtained during the first 9 days of a treatment cycle that is found to be therapeutic can subsequently predict a therapeutic trough level, albeit with a relatively high false-positive rate. Although larger studies are needed before these recommendations can be incorporated into everyday clinical practice, this study adds further valuable understanding of the utility of therapeutic drug monitoring for anti-TNF therapies in patients with Crohn's disease.
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Shaded areas on the logistic regression curves indicate 95% confidence limits for the probability of achievement of a therapeutic level at trough. DL1 = drug level at visit 1, DL2 = drug level at visit 2. TL = 1 indicates achievement of a therapeutic trough level (≥4.9 lg/mL).
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